TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Potentially-resectable, histologically proven recurrent GBM~2. Subject must be ≥ 18 years of age~3. Subject must have a Karnofsky Performance Score ≥ 70%~4. Subject must have had a T1 weighted 3D MRI with Gadolinium enhancement within fourteen (14) days prior to surgery~5. Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment~6. Subjects of child-bearing potential must agree to use adequate contraceptive precautions and not to breastfeed (if applicable)~Exclusion Criteria:~1. More than three relapses~2. Subject has multi-centric disease~3. Subject has tumors in or near (less than 10mm from tumor margin) critical brain structures, that would exclude sufficient dose delivery to the tumor: such as:~   1. Optic Chiasm~  2. Optic Nerve~4. Women who are pregnant or nursing. Women with child-bearing potential or sexually active men that are not willing/able to use medically acceptable forms of contraception~5. Subject has contraindications for MRI with or without gadolinium injections~6. Subject has contraindications for anesthesia or surgery~7. Subject is on another therapeutic clinical trial concurrently~8. Subject had previous radiation for GBM less than 3 month earlier~9. Prior history of standard dose of Central Nervous System (CNS) of more than 60 Gy~Intra-Operative Exclusion Criteria~1. Frozen section does not show any sign of malignant tissue~2. Dose at any organ at risk will exceed 10 Gy including:~   1. Chiasm~  2. Optic Nerve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-operative Radiation Therapy - IORT (Type: EXPERIMENTAL): Intra-operative Radiation Therapy - IORT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Treatment of Complex Anal Fistulas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with complex transsphincteric anal fistulas \>18 yrs old.~Exclusion Criteria:~* Crohns fistulas~* Signs of suppuration or/and branching.~* Malignancy within 5 yrs.~* Previous radiotherapy of the abdomen and pelvis.~* Current Immune- suppressive treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Operation (Type: ACTIVE_COMPARATOR): the fistula will be excised after dividing the sphincter and primary reconstruction~.
- VAAFT (Type: EXPERIMENTAL): the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of both genders with mild to severe HF as defined as NHYA Class II to IV who also have an indication for device implant according to ESC/AHA guidelines as well as having a HF hospitalization or Emergency Department visit necessitating therapy within the past 12 months and who meet all inclusion criteria and no exclusion criteria, are eligible for this study.~Exclusion Criteria:~* Subject is post heart transplant or actively listed on the transplant list and reasonable probability (as defined by investigator) of undergoing transplantation in the next year~* Subject received a coronary artery bypass graft or valve surgery in last 90 days~* Subject with a myocardial infarction (MI) in the last 40 days.~* Subject's life expectancy is less than one year in the opinion of the physician~* Subject has severe Chronic Obstructive Pulmonary Disease (COPD), as determined by physician and documented in medical records~* Subject is listed for valve replacement/valve repair~* Subject has severe, primary pulmonary hypertension as determined by physician and documented in medical records~* Subject with serum creatinine ≥ 2.5 mg/dL measured within 14 days prior to enrolment~* Subject on chronic renal dialysis~* Subject on continuous or uninterrupted (≥ 2 stable infusions per week) infusion (inotropic) therapy for HF~* Subject has complex and uncorrected Congenital Heart Disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Access Arm (Type: EXPERIMENTAL): HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
- Control arm (Type: ACTIVE_COMPARATOR): HF subjects managed with standard clinical assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Glycemic Load on Body Composition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight or obese adults~Exclusion Criteria:~* Subjects who are pregnant or have diabetes, cancer, psychiatric disorders or physical disabilities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): This group will receive a low glycemic load
- B (Type: ACTIVE_COMPARATOR): This group will receive a high glycemic load

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Case Collection Study for Collecting Images for the Development and Validation of Computer Aided Detection Software

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Mammograms obtained from women 40 years of age and over;~2. Mammograms obtained from women only;~3. There are at least four standard views (right cranio-caudal \[RCC\], right medio-lateral oblique \[RMLO\], left cranio-caudal \[LCC\], left medio-lateral oblique \[LMLO\]) of the breast;~4. Informed consent is obtained.~   Mammograms of biopsy-proven cancer cases will be considered eligible for inclusion in the study if they meet the following criteria:~5. Biopsy-proven malignant case that was assigned a BI-RADS category 4 or 5 with a suspicious lesion and the corresponding pathology report for the suspicious lesion is available.~6. Cases which have one or more lesion.~   Routine screening Normal cases will be considered eligible for inclusion in the study if they meet the following criteria:~7. The case is a routine screening mammogram assigned a BI-RADS category 1 or 2 by a certified radiologist~Exclusion Criteria:~Cases are excluded from the study if they have any of the following conditions:~1. Mammographic needle projection or pre-biopsy markings are evident on the mammogram (these may cause false marks).~2. The mammograms include artifacts created by breast implant.~3. The mammograms are of poor quality (e.g., the digital image has very poor contrast);~   Mammograms of biopsy-proven cancer cases will be excluded from the study if they have any of the following conditions:~4. Cases in which the lesion is only palpable or visible by another modality (e.g., Ultrasound, MRI).~5. The pathology is not related to a specific region. That is, there is more than one biopsy region and the pathology reports cannot be related to the appropriate mammographic lesion. For example, a mammogram with multiple lesions and multiple related pathology reports on the same date and it is not clear which pathology report belongs to each lesion.~6. The pathology report is more than three months after the FFDM or FSM mammogram.~7. The mammogram was performed for the purpose of planning cancer therapy (e.g., radiation) (BIRADS 6).~8. Cases in which the lesion is characterized as an architectural distortion. -

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mammography Image Collection (Type: None): Acquired images
- CAD Radiologist Reader (Type: None): Retrospective reader study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Metabolic Response in Critically Ill Patients With Acute Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 18 years of age admitted to the intensive care unit~* New onset acute renal failure (ARF) or ARF superimposed on chronic kidney disease~* ARF will be defined by a sustained (over 24 hours) increase in serum creatinine \> 0.5 mg/dl from baseline~* Patients will be recruited for the study within 3-5 days following establishment of ARF~Exclusion Criteria:~* Institutionalized patient~* Previous kidney transplant~* Pregnancy~* Unable to obtain consent from subject or legally recognized representative~* ARF from urinary tract obstruction or a volume responsive pre-renal state.~* Liver Failure~* Recent cerebrovascular accident (CVA)~* Coagulopathy defined as: Platelets \< 50, PT \> 20, INR \> 2.0 if the patient requires the placement of an arterial or venous catheter; if the patient does not require the placement of an arterial or venous catheter for the study, coagulopathy will not be a basis for exclusion.~* Life expectancy \< 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): supplement contains protein content of 1.4 g/kg/day
- 2 (Type: ACTIVE_COMPARATOR): supplement contains protein content of 2.0 g/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed uveal melanoma~* Monosomy 3 status (by fluorescent in situ hybridization \[FISH\] or multiplex ligation-dependent probe amplification \[MLPA\]) or DecisionDx class 2~* Tumor thickness \> 3.0 mm~* Has received definitive treatment of uveal melanoma with brachytherapy, proton therapy, stereotactic radiosurgery, or enucleation~* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG)~* Total bilirubin \< 1.5 mg/dl~* Aspartate transaminase (AST) up to two times normal limit~* Alanine transaminase (ALT) up to two times normal limit~* Creatinine \< 2.0 mg/dl~* Functional left kidney based on computed tomography (CT) imaging~* Positron emission tomography (PET)/CT demonstrating no evidence of metastatic disease~* If a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use contraception for the duration of radiation therapy (approximately 3 weeks)~* Understands the trial and procedures and is willing and able to sign the Informed Consent Form~Exclusion Criteria:~* Previous malignancy, other than localized cutaneous squamous cell carcinoma or basal cell carcinoma~* History of prior irradiation to the thorax or abdomen~* Inadequate hepatic or kidney function (as specified above)~* Active peptic ulcer disease~* Upper gastrointestinal bleeding~* Pregnant women or women that refuse to use contraception throughout the entire study period~* Currently receiving chemotherapy~* Refuses to sign the informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (external beam radiation therapy) (Type: EXPERIMENTAL): Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Review of Descending Aortic Flow Reversal in Total Anomalous Pulmonary Venous Connection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children's Healthcare of Atlanta and Sibley Heart Center Cardiology charts and echocardiograms of the TAPVC patients between January 1, 2002 and November 26, 2006 will be reviewed. We anticipate approximately 40 patients.~The patients with TAPVC will be divided into two groups by the presence or absence of descending aortic flow reversal.~Exclusion Criteria:~* those who do not fall under the Inclusion Criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* confirmed COVID-19~* Within 48 hours of presentation in the emergency department, high dependency area or intensive care unit (ICU)~* ARDS according to Berlin definition (P/F \< 300) or O2 saturation \< 90% or RR \> 30/min) in room air~* Standard oxygen therapy at flow rate \< 15L/min x 60 minutes~Exclusion Criteria:~* More than 48 hours of admission to the emergency department, high dependency or intensive care unit~* More than 4 hours on NIV or HFNC before enrolment~* Impending cardiopulmonary arrest~* Need for immediate endotracheal intubation~* Hemodynamic instability or life-threatening arrhythmias~* GCS \< 8~* Active intracranial pathology or high ICP~* Inability to cooperate or protect the airway~* Pregnancy~* Tracheostomy~* DNR or refusing intubation~* Known type 2 respiratory failure~* On chronic home oxygen therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: OTHER): Face-mask NIV is the standard of care
- intervention 1 (Type: ACTIVE_COMPARATOR): High flow nasal cannula
- Intervention 2 (Type: ACTIVE_COMPARATOR): Helmet NIV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female residents of LTCFs at least 55 years of age.~* Willing and able to provide written informed consent and comply with the requirements of the protocol.~* At least one symptomatic laboratory-confirmed COVID-19 illness identified among residents or staff of the LTCF within 10 days prior to randomization.~Exclusion Criteria:~* Alzheimer's disease, dementia, or other mental incapacity which precludes comprehension of the study requirements or symptom diary.~* Subjects expected to require hospitalization within the 8-week treatment and follow-up period.~* Subjects with a history of COVID-19 or known to have developed anti-SARS- CoV-2 antibodies.~* Subjects who experienced a previous episode of acute upper respiratory tract infection, otitis, bronchitis or sinusitis or received antibiotics for these conditions or antiviral therapy for influenza within two weeks prior to and including study day 1.~* Receipt of any dose of NTZ within 7 days prior to screening.~* Treatment with any investigational drug or vaccine within 30 days prior to screening or unwilling to avoid them during the course of the study.~* Known sensitivity to NTZ or any of the excipients comprising the study medication.~* Subjects unable to swallow oral tablets or capsules.~* Subjects taking medications considered to be major CYP2C8 substrates.~* Subjects who, in the judgment of the Investigator, will be unlikely to comply with the requirements of this protocol.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Nitazoxanide (Type: ACTIVE_COMPARATOR): Two Nitazoxanide 300 mg tablets orally twice daily for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Two placebo tablets orally twice daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women, aged 18-85 with who have previously had the InterStim device implanted and have experienced good control of their symptoms for at least one year.~Exclusion Criteria:~* Patients with less than 6 months of expected battery life on their device established at office testing.~* Patients with poor control of their symptoms within the last one year.~* Patients with degenerative neurological disorders or spinal cord injuries.~* Patients with cognitive disabilities or those lacking the mental capacity to understand and answer questionnaires.~* Patients who are pregnant or may become pregnant.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Sacral neuromodulation device turned off (Type: OTHER): Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects and Mechanism of Guided Virtual Reality Autogenic Meditation on ICU Sleep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 20 years and above.~* Clear consciousness and able to communicate with Chinese or Mandarin.~* Expect to stay in ICU for more than 72 hrs~Exclusion Criteria:~* The use of invasive mechanical ventilation.~* Having visual or hearing difficulty~* Having a medical history of sleep disorder, cognition impairment, psychiatric disorders, or seizures.~* Having sedation use~* Having APACHE II over 25

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Virtual reality (Type: EXPERIMENTAL): Participants will receive virtual reality for 30 minutes before bedtime and then will be placed on an eye mask for a whole night's sleep for consecutive two days or until discharge from ICU. A total treatment dosage of 60 minutes is required.
- Eye masks (Type: EXPERIMENTAL): Participants will receive eye masks during their sleep for consecutive two days or until discharge from ICU.
- Control group (Type: NO_INTERVENTION): The control group only receive routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues